Harel Issuances In 2025: The Tiny Profit Is Noise, Rating And Capital Are The Story

Company Overview

At first glance, Harel Issuances looks like a company with a NIS 6.24 billion balance sheet and a tiny NIS 2.5 million net profit. That is the wrong way to read it. This is not an insurer, not a lending franchise, and not a debt issuer trying to earn a spread for itself. It is a dedicated funding conduit for Harel Insurance: it raises debt in the market, passes the proceeds upstream to Harel Insurance, and is designed to end up with almost no standalone profit.

What is actually working now is the funding machine itself. In 2025 the company issued NIS 1 billion in Series 21, carried out a partial debt exchange that created Series 22 and 23, and exited the period with a rating upgrade after the balance-sheet date. What is still not clean is just as important: practically the entire asset base is exposure to one counterparty, Harel Insurance. Anyone trying to read this through the P&L will miss the point, and anyone trying to read it as a standalone debt credit will miss the risk concentration.

That is also the early actionability filter. The company has no listed common equity and effectively trades only through its bond series. So this is not an "equity story" in the usual sense. The relevant question is whether Harel Insurance can keep using this vehicle to raise regulatory capital and refinance debt efficiently, not whether Harel Issuances itself is building an operating franchise.

The right screen for 2026 is straightforward. If Harel Insurance keeps underwriting profitability, solvency, and market access in good shape, Harel Issuances remains an efficient capital-market tool. If the parent insurer's profitability proves too dependent on supportive markets, or if solvency weakens, this issuer has almost no standalone cushion to absorb the pressure.

Quick orientation:

The important point is that this growth does not diversify risk. It does the opposite. The two lines that drove asset growth, the deferred deposit and the parent current account, are simply two forms of the same exposure to Harel Insurance. That is an efficient structure when the parent is strong. It is a very thin structure if the parent credit profile weakens.

Events And Triggers

The first trigger: in April 2025 the company issued NIS 1 billion of Series 21, with a fixed 5.85% coupon and final principal repayment in June 2074. This is not just another plain bond series. The instrument was recognized as Additional Tier 1 capital for Harel Insurance, and its terms allow coupon cancellation, full or partial principal write-down, and principal deferral under certain circumstances. In other words, the group did not merely raise funding. It added a regulatory capital layer through the subsidiary.

The second trigger: in August and September 2025 the company launched a partial exchange offer for Series 16. Holders tendered NIS 321.1 million par value, the company accepted exchanges for NIS 293.1 million par value, and in return issued NIS 149.1 million par value each of Series 22 and Series 23. The exchange ratio was set at 1.017. The point here is not just technical liability management. The company used a supportive market window to reshape the debt stack, not merely to grow it.

The third trigger: on December 31, 2025, Series 9 was fully redeemed. This is smaller than the Series 21 story, but it matters because it shows the company is actively maintaining the legacy stack rather than only adding new paper on top.

The fourth trigger: after the balance-sheet date, on February 5, 2026, Midroog upgraded Harel Insurance's financial strength rating from Aa1.il to Aaa.il, and upgraded the relevant subordinated instruments issued through Harel Issuances from Aa3.il(hyb) to Aa2.il(hyb), with a stable outlook. A few days later, on February 18, 2026, a new shelf prospectus was published. That combination matters more than the issuer's 2025 net profit because it makes the right lens unmistakable: this is a read on Harel Insurance credit quality and capital strength much more than on issuer earnings.

Timing mattered. The company itself describes 2025 as a positive year for the Israeli bond market, with roughly 6% annual returns in the corporate bond index and about NIS 13 billion of net inflows into general bond mutual funds. That is not throwaway macro color. It is exactly the backdrop that made both the Series 21 issue and the Series 16 exchange possible.

Efficiency, Profitability And Competition

This is not a spread business, and that is by design

Anyone trying to measure Harel Issuances like a normal business will end up in the wrong place. The company is not built to earn a spread between funding cost and asset yield. In 2025 interest income was NIS 256.5 million, and interest expense was exactly the same, NIS 256.5 million. Expense reimbursement from the parent was NIS 1.742 million, and G&A expense was also NIS 1.742 million.

In other words, the core operating model nets to zero. That is not a malfunction. It is the architecture.

That means 2025 profit did not come from better operating economics. It came almost entirely from income related to expected credit-loss provisioning of NIS 2.487 million. The equity deficit tells the same story from another angle. The company ended 2025 with a NIS 6.0 million equity deficit, almost identical to the NIS 6.003 million expected credit-loss reserve at year-end. This is the key point. The issuer is not operationally bleeding. It is carrying a credit reserve against its exposure to Harel Insurance.

Series 21 created large accounting noise, not large economic profit

Series 21 changed the shape of the financial statements more than it changed recurring economics. Because the matching deposit can be written down under certain circumstances, the company concluded that the asset does not qualify for amortized-cost measurement and instead measures it at fair value through profit or loss. To avoid an accounting mismatch, the Series 21 liability was also designated at fair value through profit or loss.

The result in 2025 was NIS 94.3 million of finance income from fair-value changes in the asset, and at the same time NIS 94.3 million of finance expense from fair-value changes in the liability. Anyone reading only the headline lines will see a sharp jump in activity. In practice, this is mostly a symmetric gross-up on both sides of the income statement.

The Series 16 exchange created a smaller version of the same dynamic. The company recorded NIS 1.671 million of finance income from the bond exchange, and at the same time NIS 1.671 million of finance expense from exchanging the matching deferred deposits. Again, this is an accounting event, not a new earnings engine.

The quarterly split makes the point even clearer. The company lost NIS 78 thousand in the first quarter, earned NIS 52 thousand in the second, and NIS 210 thousand in the third. Only in the fourth quarter did profit rise to NIS 2.303 million. This is not a company with a steadily improving earnings curve. Reported profit mostly reflects credit-risk remeasurement and the way exposures to the parent are accounted for.

The real competitive position sits at Harel Insurance, not at the issuer

At first sight, a "competition" section sounds odd for a company like this. In reality, competition exists here, but it sits at the parent level. Midroog describes Harel Insurance as Israel's largest insurer, with roughly 21% gross premium market share in 2024 and about NIS 139 billion of assets under management as of September 30, 2025. That is what gives Harel Issuances market access. Not the subsidiary's own brand, and certainly not standalone profitability that barely exists.

This is also where the other side of the story matters. Midroog links the upgrade to a material and sustained improvement in underwriting profit and profitability metrics, but the same report also says profitability was supported by significant investment and financing gains due to capital-market returns. So credit quality improved, but not every part of the improvement is pure underwriting strength. For Harel Issuances that distinction matters a lot: if market conditions reverse, the issuer itself has no internal earnings engine to offset it.

Cash Flow, Debt And Capital Structure

Cash flow: every shekel is passed through

It is worth defining the cash frame explicitly. In this case the right frame is all-in cash flexibility at the issuer level. That asks how much cash is left after all actual cash uses. The answer in 2025 is effectively zero, and that is by design.

In financing cash flow the company received NIS 995.0 million from debt issuance, net of issuance costs, and paid NIS 348.1 million on debt repayments. Net financing inflow was NIS 646.9 million. In investing cash flow it placed NIS 995.0 million into deferred deposits and received NIS 348.1 million from deferred deposit repayment. Net investing outflow was NIS 646.9 million. The end result is no change in cash.

Anyone looking for free cash flow here is looking at the wrong object. This is not an operating business that generates cash and then decides what to do with it. It is a conduit that turns debt issuance into exposure to Harel Insurance.

Capital structure: large debt stack, almost no standalone cushion

At December 31, 2025 the company had NIS 6,245.8 million of debt securities outstanding. Net deferred deposits were NIS 5,589.5 million, alongside NIS 650.6 million of current-account exposure to the parent. On a gross basis, related-party exposure stood at NIS 5,594.7 million in deferred deposits and NIS 651.3 million in the parent current account, together NIS 6,246.0 million. That is essentially a mirror image of the liability side.

That is why the NIS 6.0 million equity deficit does not reflect an operating-capital problem. It reflects, almost entirely, the fact that the gross exposure to Harel Insurance is reduced by the expected credit-loss reserve. This is material because it means the issuer's standalone cushion is extremely thin, and because the 2025 improvement came mainly from lower provisioning rather than from internally generated capital.

The parent current account also grew sharply, from NIS 336.4 million gross at the end of 2024 to NIS 651.3 million gross at the end of 2025, and during the year it reached a peak of NIS 953.0 million. That does not diversify risk. It simply means a larger share of the asset base now sits as a current exposure to the same parent rather than as a long-dated deferred deposit.

The debt stack: Series 21 is already at the top

The largest series is no longer one of the older issues. It is Series 21 at NIS 1,084.2 million of carrying value. Then come Series 14 at NIS 728.3 million, Series 18 at NIS 687.5 million, Series 15 at NIS 681.2 million, Series 19 at NIS 496.9 million, and Series 20 at NIS 494.9 million. Those buckets alone make up the majority of the debt stack.

There is also a meaningful difference between layers. Series 10 through 18 are recognized by Midroog as Tier 2 or complex secondary capital instruments, while Series 21 serves as Additional Tier 1. That matters because the more the structure leans on capital-like instruments, the more the relevant question becomes Harel Insurance solvency and rating strength rather than the issuer's own earnings profile.

It is also important to note what is not there. The debt securities are not secured by any collateral. The company is allowed to issue additional debt, including debt with equal, higher, or lower ranking. On the other hand, Harel Insurance committed to the trustee to fulfill the payment terms of principal, linkage, and interest. So the support here is not a ring-fenced asset package. It is the parent's credit standing.

Outlook

Finding one: 2025 reported profit says almost nothing about earning power. It mainly says the market-implied credit read on Harel Insurance improved.

Finding two: Series 21 improved the group's capital toolkit, but it also brought accounting volatility that does not say much about underlying spread economics.

Finding three: the equity deficit is almost identical to the expected credit-loss reserve. Any change in the parent's credit quality can therefore move almost directly through the issuer's equity line.

Finding four: the February 2026 rating upgrade and the new shelf prospectus mean the next test is not another P&L line from the issuer. It is whether Harel Insurance can continue to use this company as an efficient capital-market machine.

That makes 2026 look like a proof year for the capital machine, not an operating breakout year. There is no new product to commercialize and no margin story to scale. The test is different: whether the rating upgrade really lowers funding cost, whether Harel Insurance solvency stays comfortably away from capital-instrument triggers, and whether parent profitability keeps coming from underwriting strength rather than only from supportive markets.

The Midroog context strengthens that view, but it does not remove the need to keep testing it. On the positive side, Midroog points to underwriting improvement, ROC of 19.1% in the first nine months of 2025 versus 12.1% in 2024, and solvency ratios of 183% with the transitional period and 159% without it as of June 30, 2025. On the other hand, the same report highlights a still restrictive macro backdrop, capital-market volatility, regulatory pressure, and competition in health and general insurance. So the issue is not whether Harel Insurance looks strong today. The issue is whether that strength is stable enough to support the next funding cycle.

What has to happen over the next 2 to 4 quarters for the thesis to strengthen is therefore clear. First, solvency updates at Harel Insurance need to stay comfortably above the relevant trigger zone for capital instruments. Second, if the company taps the new shelf prospectus, the next set of issuance terms should show that the rating upgrade translated into better cost of capital, or at minimum preserved easy market access. Third, expected credit-loss provisioning should not start widening again if the parent credit profile really is improving. Fourth, Harel Insurance needs to keep showing that underwriting profitability was not just a one-period benefit from strong markets.

What would break this read is also clear. If parent profitability weakens, solvency compresses, or the market backdrop for capital instruments turns materially harder, Harel Issuances does not provide an independent buffer. It will reflect that deterioration very quickly.

Risks

Almost all risk is concentrated in one counterparty

The company states that it is not materially exposed to market and liquidity risk because issuance proceeds are deposited with Harel Insurance on terms similar to the debt instruments. That is true, but only half the story. The price of that structure is near-total credit concentration in Harel Insurance. The issuer's risk is therefore not diversified. It is overwhelmingly concentrated in one parent exposure.

Series 21 improves capital quality, but adds instrument complexity

Series 21 is recognized as Additional Tier 1 capital. That is clearly beneficial for the group. But the same benefit comes with coupon-cancellation terms, principal write-down mechanics, and deferral features. As long as Harel Insurance stays far from the trigger zone, this is an efficient capital layer. If that distance narrows, the instrument starts to matter for risk in a way plain debt would not.

There is almost no standalone cushion

The company has an equity deficit, no independent operating engine, no salary expense for senior officers because those costs are borne at the group level, and no collateral securing its debt stack. That does not mean the debt is in immediate trouble. It does mean investors are relying almost entirely on the parent rather than on any standalone resilience at the issuer.

Even the upgrade does not remove market dependence

Midroog's own report says the improvement in profitability was supported not only by underwriting, but also by investment and financing gains. It also points to regulatory pressure and increasing competition. So the upgrade is an important signal, but it does not eliminate the degree to which this story still depends on markets and on the parent's ability to preserve profitability and capital strength over time.

Conclusions

Harel Issuances ended 2025 in a better position as a group financing tool, not as a standalone business. What supports the thesis is a large regulatory-capital issue, a refinancing move, and a post-balance-sheet rating upgrade. What prevents a cleaner read is that the company itself still has almost no independent earnings engine or equity cushion, so the market will keep reading it through Harel Insurance rather than through the issuer's own reported profit.

Current thesis in one line: Harel Issuances is effectively a listed credit window on Harel Insurance, and in 2025 that window improved mainly because of stronger rating and capital tools, not because of standalone profitability.

Relative to the start of 2025, three things changed in a material way: the group added an Additional Tier 1 layer through Series 21, partially reshaped the debt stack through the Series 16 exchange, and then received a rating upgrade after year-end that improves the odds of continued market access on better terms. The strongest counter-thesis is that this improved read still depends partly on supportive capital markets and on parent profitability that may not prove equally durable.

What can change the market interpretation in the near to medium term is not another issuer P&L print, but three other datapoints: Harel Insurance solvency updates, the pricing of any future issuance under the new shelf prospectus, and the direction of the expected credit-loss reserve. Why this matters is simple. This is the clearest public window into whether Harel can translate credit strength and regulatory capital capacity into real financing flexibility, or whether 2025 was mostly a favorable issuance window.

What must happen next is already visible. Harel Insurance needs to maintain strong capital ratios, preserve underwriting profitability, and show that the next time it comes to market it can do so without paying a heavier funding cost. What would weaken the read is equally visible: any deterioration in the parent's credit strength would flow through this issuer almost immediately.